SVB Securities analyst Thomas Smith maintained a Buy rating on Equillium (EQ – Research Report) on March 23 and set a price target of $7.00. The company’s shares closed yesterday at $0.71.
According to TipRanks, Smith is a 5-star analyst with an average return of 24.4% and a 40.52% success rate. Smith covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, Celldex, and Intercept Pharma.
Equillium has an analyst consensus of Strong Buy, with a price target consensus of $5.60, a 693.43% upside from current levels. In a report released on March 24, Cantor Fitzgerald also maintained a Buy rating on the stock with a $2.80 price target.
See today’s best-performing stocks on TipRanks >>
EQ market cap is currently $24.95M and has a P/E ratio of -0.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
Read More on EQ:
